Eli Lilly’s Dual Catalysts: Immunology Data and Analyst Confidence

Investors in Eli Lilly have received two distinct but significant pieces of news this week, highlighting the pharmaceutical giant’s growth drivers beyond its headline-grabbing GLP-1 franchise. Fresh long-term clinical data for an immunology drug and a bullish initiation from a major bank underscore the company’s broader strategic strength.

Barclays Highlights Lilly as a Top Pick with $1,350 Target

Analyst sentiment provided a clear boost on Thursday. Barclays commenced coverage of Eli Lilly with an “Overweight” rating, designating it as a top selection among large-cap U.S. pharmaceutical stocks. Analyst Emily Field set a price target of $1,350 per share, implying an approximate 32% upside from the level at the time of the report.

The bank’s rationale centers on the enduring potential of obesity therapies, which it views as a “lasting structural shift.” Barclays expects Lilly to maintain its leadership position, specifically praising the efficacy and safety profile of its tirzepatide product. The firm also cited Lilly’s direct-to-consumer platform, “Lilly Direct,” as a competitive advantage in the space.

Omvoh Demonstrates Sustained Efficacy in Crohn’s Disease Over Three Years

Separately, Eli Lilly presented compelling long-term Phase 3 data for its Crohn’s disease treatment, Omvoh (mirikizumab), at the ECCO congress in Stockholm. The findings from the VIVID-2 open-label extension study revealed strong durability of response.

For patients who achieved steroid-free remission after one year of treatment, over 90% maintained this disease control through three years of continuous Omvoh therapy. Specifically, 92.4% of patients with endoscopic response at one year sustained clinical remission at three years, and 91.2% did so without corticosteroids. The drug also showed meaningful impact on daily symptoms, with 71.7% achieving sustained bowel urgency remission and 82.1% maintaining measurable improvements.

Should investors sell immediately? Or is it worth buying Eli Lilly?

Additional data from the VIVID-1 and LUCENT-3 studies indicated that Omvoh significantly reduced Crohn’s-related hospitalizations and surgeries—by nearly half in the first 12 weeks compared to placebo and by almost 70% between weeks 12 and 52. For ulcerative colitis, Lilly reported only one hospitalization and zero surgeries in the three-year extension study. Now approved in 47 countries, these long-term results bolster Lilly’s standing in the lucrative market for inflammatory bowel diseases.

Near-Term Catalysts and Current Trading Dynamics

The immediate calendar holds a key regulatory event. According to Reuters, the U.S. FDA is expected to issue a decision on Lilly’s oral GLP-1 tablet, orforglipron, by April 10th. The company has signaled serious commercial preparation, disclosing in a mandatory filing that it had built $1.5 billion in advanced inventory for the launch by year-end, up from roughly $550 million the prior year.

Despite these positive developments, Eli Lilly’s shares have recently exhibited weakness. The stock closed at €857.00 on Friday, marking a 7.14% decline over the preceding 30-day period. Technically, the equity appears oversold in the short term, with a 14-day Relative Strength Index reading of 28.5.

Market attention will now focus on two factors: the impending FDA verdict on orforglipron in April, and the company’s ability to translate the robust Omvoh data into tangible momentum for its immunology business. Success on the latter front would further demonstrate a reduced reliance on the GLP-1 segment alone.